Home Clinical Topics FDA approves new drug for schizophrenia and new drug for lung cancer

FDA approves new drug for schizophrenia and new drug for lung cancer

On July 13, the U.S. Food and Drug Administration (FDA) approved

  • Rexulti (brexpiprazole) to treat adults with schizophrenia and as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder. Read more
  • Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors harbor specific types of epidermal growth factor receptor gene mutations, as detected by an FDA-approved test. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here